Dear Dr Hyrich,

<table>
<thead>
<tr>
<th>IRAS Project ID:</th>
<th>64202</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short Study Title:</td>
<td>Prospective observational study of the long-term hazards of anti-TNF therapy in rheumatoid arthritis</td>
</tr>
<tr>
<td>Amendment No./Sponsor Ref:</td>
<td>26</td>
</tr>
<tr>
<td>Amendment Date:</td>
<td>19 September 2018</td>
</tr>
<tr>
<td>Amendment Type:</td>
<td>Substantial Non-CTIMP</td>
</tr>
</tbody>
</table>

I am pleased to confirm **HRA and HCRW Approval** for the above referenced amendment.

You should implement this amendment at NHS organisations in England and Wales, in line with the conditions outlined in your categorisation email.

**User Feedback**

The Health Research Authority is continually striving to provide a high quality service to all applicants and sponsors. You are invited to give your view of the service you have received and the application procedure. If you wish to make your views known please use the feedback form available on the HRA website: [http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/](http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance/).

Please contact [hra.amendments@nhs.net](mailto:hra.amendments@nhs.net) for any queries relating to the assessment of this amendment.

Kind regards

**Mrs Kirsten Peck**  
**HRA Approval Amendment Coordinator**  
**Health Research Authority**  
Ground Floor | Skipton House | 80 London Road | London | SE1 6LH  
E. [hra.amendments@nhs.net](mailto:hra.amendments@nhs.net)  
W. [www.hra.nhs.uk](http://www.hra.nhs.uk)

Sign up to receive our newsletter **HRA Latest**.